Adams Clinical — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$74,474	49
2024	Research	$2,013,623	2
2023	Research	$20,387	1
2021	Research	$23,224	6
2020	Research	$15,265	5
2019	Research	$89,376	6

Breakdown

Who paid Research payments · program years 2019–2025

Boehringer Ingelheim International GmbH $2,088,097 51 payments
Supernus Pharmaceuticals, Inc. $104,366 9 payments
ACADIA Pharmaceuticals Inc $23,499 8 payments
Sage Therapeutics, Inc. $20,387 1 payment

Studies the money was for Research payments · program years 2019–2025

Phase II DRF study of NR2B modulation in MDD $2,013,623 2 payments
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD $74,474 49 payments
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Spn-812 Er for the Treatment of Pediatric Patients With Attention Deficithyperactivity Disorder Adhd $40,925 2 payments
Evaluation of Spn-812 Er 200 and 400 MG Efficacy and Safety in Children With Adhd - A Double-Blind, Placebo-Controlled, Pivotal Trial $26,523 1 payment
Evaluation of Spn-812 Er 400 and 600 MG Efficacy and Safety in Adolescents With Adhd - A Double-Blind, Placebo- Controlled, Pivotal Trial $21,927 3 payments
Acp-103-055 $20,440 6 payments
A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment with SAGE-217 in Adult Subjects with Major Depressive Disorder $20,387 1 payment
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Spn-812 Er for the Treatment of Pediatric Patients With Attention Deficit/Hyperactivity Disorder (Adhd) $14,991 3 payments
Acp-103-059 $3,060 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.